143 related articles for article (PubMed ID: 35027434)
1. Clinical Utility of Reflex Testing with Cancer Biomarkers to Improve Diagnostic Accuracy of Primary Human Papillomavirus Screening.
Johnson LG; Saidu R; Svanholm-Barrie C; Boa R; Moodley J; Tergas A; Persing D; Campbell SA; Tsai WY; Wright TC; Denny L; Kuhn L
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):595-603. PubMed ID: 35027434
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study.
Kuhn L; Saidu R; Boa R; Tergas A; Moodley J; Persing D; Campbell S; Tsai WY; Wright TC; Denny L
Lancet Glob Health; 2020 Feb; 8(2):e296-e304. PubMed ID: 31981559
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.
Song F; Du H; Wang C; Huang X; Qu X; Wei L; Belinson JL; Wu R;
J Med Screen; 2021 Sep; 28(3):318-324. PubMed ID: 32869705
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
[TBL] [Abstract][Full Text] [Related]
6. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
7. Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus.
Strickler HD; Keller MJ; Hessol NA; Eltoum IE; Einstein MH; Castle PE; Massad LS; Flowers L; Rahangdale L; Atrio JM; Ramirez C; Minkoff H; Adimora AA; Ofotokun I; Colie C; Huchko MJ; Fischl M; Wright R; D'Souza G; Leider J; Diaz O; Sanchez-Keeland L; Shrestha S; Xie X; Xue X; Anastos K; Palefsky JM; Burk RD
Clin Infect Dis; 2021 May; 72(9):1529-1537. PubMed ID: 32881999
[TBL] [Abstract][Full Text] [Related]
8. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
11. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
12. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
[TBL] [Abstract][Full Text] [Related]
13. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
14. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
15. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
16. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
17. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
20. Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age.
Malagón T; Louvanto K; Ramanakumar AV; Koushik A; Coutlée F; Franco EL;
Gynecol Oncol; 2019 Nov; 155(2):245-253. PubMed ID: 31604665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
